LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Another widespread trait among modern birds (but see below in regards to fossil groups and extant megapodes) is parental care for young after hatching. Bob Makela and Jack Horner's 1978 discovery of a Maiasaura ("good mother lizard") nesting ground in Montana demonstrated that parental care continued long after birth among ornithopods. A specimen of the oviraptorid Citipati osmolskae was discovered in a chicken-like brooding position in 1993, which may indicate that they had begun using an insulating layer of feathers to keep the eggs warm. An embryo of the basal sauropodomorph Massospondylus was found without teeth, indicating that some parental care was required to feed the young dinosaurs. Trackways have also confirmed parental behavior among ornithopods from the Isle of Skye in northwestern Scotland. However, there is ample evidence of precociality or superprecociality among many dinosaur species, particularly theropods. For instance, non-ornithuromorph birds have been abundantly demonstrated to have had slow growth rates, megapode-like egg burying behavior and the ability to fly soon after birth. Both Tyrannosaurus and Troodon had juveniles with clear superprecociality and likely occupying different ecological niches than the adults. Superprecociality has been inferred for sauropods. Genital structures are unlikely to fossilize as they lack scales that may allow preservation via pigmentation or residual calcium phosphate salts.
. It is unitless. A "high-resolution" mass analyzer typically has resolution >1 million. Concretely, that means it can resolve two peaks at ~1 kDa, differing by just ~1 mDa. The absolute accuracy is the ratio of the m/z measurement error to the true m/z. It is defined as
McDivitt, to White: I'm going out to PUSH-TO-TALK and see what the Flight Director has got to say. Flight Director Chris Kraft, to Grissom: The flight director says, get back in! (Kraft was not on the air-to-ground loop with the astronauts.) McDivitt: Gus, this is Jim. Got any message for us? Grissom: Gemini 4, get back in! McDivitt: Okay. ... (to White): ... They want you to come back in now.
==== Medical aid in dying ==== In 2021, Newsom signed Senate Bill 380, which amended the California End of Life Option Act by shortening the required interval between a patient's two oral requests for an aid-in-dying drug from 15 days to 48 hours, eliminated the requirement for a final attestation, and extended the Act's expiration date to January 1, 2031. In 2025, he signed Senate Bill 403, which repealed the provision setting that expiration date, thereby extending the Act indefinitely.
Sources: en.wikipedia.org
In 1990, Haire and Gibson estimated mendelevium metal to have an enthalpy of sublimation between 134 and 142 kJ/mol. Divalent mendelevium metal should have a metallic radius of around 194±10 pm. Like the other divalent late actinides (except the once again trivalent lawrencium), metallic mendelevium should assume a face-centered cubic crystal structure. Mendelevium's melting point has been estimated at 800 °C, the same value as that predicted for the neighbouring element nobelium. Its density is predicted to be around 10.3±0.7 g/cm3.
== S == S1 end mapping - S1 nuclease - satellite DNA - screening - SDS-PAGE - secondary structure - selection - selenium responsive proteins - sense strand - sequence - sequence motif - sequence polymorphism - sequence-tagged site - sequential epitope - severe combined immunodeficiency - sex chromosome - sex-linked - Shine-Dalgarno sequence - shotgun cloning - shotgun cloning or sequencing - shotgun sequencing - shuttle vector - Siah interacting protein N-terminal domain - sickle-cell disease - side chain - sigma factor - signal peptidase - signal sequence - silent mutation - single nucleotide polymorphism - siRNA - site-directed mutagenesis - site-specific recombination - Slc22a21 - slot blot - SNP - Slc22a21 - SMCR2 - snRNA - snRNP - solution hybridization - somatic cells - Southern blot - southwestern blot - SP6 RNA polymerase - SpAB protein domain - spectral karyotype - splicing - Simple Sequence Repeats (SSR) - SPR domain - SQ2397 - SRG1 RNA - ST7-AS2 - ST7-OT3 - stable transfection - start codon - stem-loop - sticky end - stomoxyn - stop codon - streptavidin - stringency - structural motif - sub-cloning - substitution - succinate—citramalate CoA-transferase - suicide gene - sulfate-transporting ATPase - suPARnostic - supercoil - SurE, survival protein E - Syb-prII-1 - syndrome -
A few of the latter are so rare that they were not discovered in nature, but were synthesized in the laboratory before it was determined that they exist in nature: technetium (element 43), promethium (element 61), astatine (element 85), neptunium (element 93), and plutonium (element 94). No element heavier than einsteinium (element 99) has ever been observed in macroscopic quantities in its pure form, nor has astatine; francium (element 87) has been only photographed in the form of light emitted from microscopic quantities. Of the 94 natural elements, eighty have a stable isotope and one more (bismuth) has an almost-stable isotope (with a half-life of 2.01×1019 years, over a billion times the age of the universe). Two more, thorium and uranium, have isotopes undergoing radioactive decay with a half-life comparable to the age of the Earth. The stable elements plus bismuth, thorium, and uranium make up the 83 primordial elements that survived from the Earth's formation. The remaining eleven natural elements decay quickly enough that their continued trace occurrence rests primarily on being constantly regenerated as intermediate products of the decay of thorium and uranium. All 24 known artificial elements are radioactive.
The most expensive process was to preserve the body by dehydration and protect against pests, such as insects. Almost all of the actions Herodotus described served one of these two functions. First, the brain was removed from the cranium through the nose; the gray matter was discarded. Modern mummy excavations have shown that instead of an iron hook inserted through the nose as Herodotus claims, a rod was used to liquefy the brain via the cranium, which then drained out the nose by gravity. The embalmers then rinsed the skull with certain drugs that mostly cleared any residue of brain tissue and also had the effect of killing bacteria. Next, the embalmers made an incision along the flank with a sharp blade fashioned from an Ethiopian stone and removed the contents of the abdomen. Herodotus does not discuss the separate preservation of these organs and their placement either in special jars or back in the cavity, a process that was part of the most expensive embalming, according to archaeological evidence. The abdominal cavity was then rinsed with palm wine and an infusion of crushed, fragrant herbs and spices; the cavity was then filled with spices including myrrh, cassia, and, Herodotus notes, "every other sort of spice except frankincense", also to preserve the person. The body was further dehydrated by placing it in natron, a naturally occurring salt, for 70 days. Herodotus insists that the body did not stay in the natron longer than 70 days.
Alimentary hypoglycemia (consequence of dumping syndrome; it occurs in about 15% of people who have had stomach surgery) Hormonal hypoglycemia (e.g., hypothyroidism) Helicobacter pylori-induced gastritis (some reports suggest this bacteria may contribute to the occurrence of reactive hypoglycemia) Congenital enzyme deficiencies (hereditary fructose intolerance, galactosemia, and leucine sensitivity of childhood) Late hypoglycemia (occult diabetes; characterized by a delay in early insulin release from pancreatic beta-cells, resulting in initial exaggeration of hyperglycemia during a glucose tolerance test) "Idiopathic reactive hypoglycemia" is a term no longer used because researchers now know the underlying causes of reactive hypoglycemia and have the tools to perform the diagnosis and the pathophysiological data explaining the mechanisms. To check if there is real hypoglycemia when symptoms occur, neither an oral glucose tolerance test nor a breakfast test is effective; instead, a hyperglucidic breakfast test or ambulatory glucose testing is the current standard. The body requires a relatively constant input of glucose, a sugar produced upon digestion of carbohydrates, for normal functioning. Glucagon and insulin are among the hormones that ensure a normal range of glucose in the human body. Upon consumption of a meal, blood sugar normally rises, which triggers pancreatic cells to produce insulin. This hormone initiates the absorption of the just-digested blood glucose as glycogen into the liver for metabolism or storage, thereby lowering glucose levels in the blood.
Sources: en.wikipedia.org
== Trials == Howard Florey's team at Oxford showed that Penicillium extract killed many kinds of bacteria. Gardner and Orr-Ewing tested it against gonococcus (against which it was most effective), meningococcus, streptococcus, staphylococcus, Bacillus anthracis, actinomyces and tetanus bacterium (Clostridium tetani) and the bacteria that cause gangrene. They observed bacteria attempting to grow in the presence of penicillin, and noted that penicillin was neither an enzyme that broke the bacteria down, nor an antiseptic that killed them; rather, it was a chemical that interfered with the process of cell division. Jennings observed that it had no effect on white blood cells, and would therefore reinforce rather than hinder the body's natural defences against bacteria. She also found that unlike sulphonamides, the first and only effective broad-spectrum antibiotic available at the time, it was not destroyed by pus. Medawar found that it did not affect the growth of tissue cells.
In November 2021, CleanTechnica reported that Tesla would be opening Superchargers at 26 Buc-ee's locations in seven states. As of February 2023, there were operational Superchargers at more than half of the planned locations including in Alabama (Leeds and Robertsdale); Florida (St. Augustine); South Carolina (Florence); Tennessee (Crossville); and Texas (Bastrop, Baytown, Ennis, Giddings, Katy, Madisonville, Melissa, New Braunfels, and Wharton). Since then, more Superchargers have been added into more locations, such as in Colorado (Berthoud); Florida (Daytona Beach); Georgia (Adalrsville and Fort Valley); Kentucky (Richmond); Tennessee (Kodak); and Texas (Denton, Fort Worth, Luling, Pearland, Royse City, Temple, Terrell, and Waller).
== Cell cycle control == Cell cycle progression is controlled by ordered action of cyclin-dependent kinases (CDKs), activated by specific cyclins that demarcate phases of the cell cycle. Mitotic cyclins, which persist in the cell for only a few minutes, have one of the shortest life spans of all intracellular proteins. After a CDK-cyclin complex has performed its function, the associated cyclin is polyubiquitinated and destroyed by the proteasome, which provides directionality for the cell cycle. In particular, exit from mitosis requires the proteasome-dependent dissociation of the regulatory component cyclin B from the mitosis promoting factor complex. In vertebrate cells, "slippage" through the mitotic checkpoint leading to premature M phase exit can occur despite the delay of this exit by the spindle checkpoint. Earlier cell cycle checkpoints such as post-restriction point check between G1 phase and S phase similarly involve proteasomal degradation of cyclin A, whose ubiquitination is promoted by the anaphase promoting complex (APC), an E3 ubiquitin ligase. The APC and the Skp1/Cul1/F-box protein complex (SCF complex) are the two key regulators of cyclin degradation and checkpoint control; the SCF itself is regulated by the APC via ubiquitination of the adaptor protein, Skp2, which prevents SCF activity before the G1-S transition. Individual components of the 19S particle have their own regulatory roles.
molar concentration Also molarity, amount concentration, or substance concentration. A measure of the concentration of a chemical species, especially of a solute in a solution, in terms of the amount of the species per unit volume of solution. Molarity is typically expressed in units of moles per litre (mol/L); a solution with a concentration of exactly 1 mol/L is commonly said to be 1 molar, abbreviated 1 M. Contrast molality.
About 82% of Americans live in metropolitan areas, particularly in suburbs and outer-ring exurbs; about half of those reside in cities with populations over 50,000. In 2024, 346 incorporated U.S. municipalities had populations over 100,000, 11 cities had more than one million residents, and four cities—New York City, Los Angeles, Chicago, and Houston—had populations exceeding two million. Some 56 U.S. metropolitan areas have one million or more residents. More recently, the fastest-growing metropolitan areas were in the South, while southern metros along the Mexican border and Gulf Coast metros susceptible to hurricanes declined the most in 2025. The New York metro area, which gained the most new residents in 2024, fell to 13th in 2025, due to a fall in immigrants. The top metro areas with rising populations in 2025 were Houston and Dallas–Fort Worth, followed by Atlanta, Phoenix and Charlotte.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.